Towards Genomic Medicine: A Tailored Next-Generation Sequencing Panel for Hydroxyurea Pharmacogenomics in Tanzania
Authors:
Preprint
- 25 August 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Pharmacogenomics of hydroxyurea is an important aspect in the management of sickle cell disease (SCD), especially in the era of genomic medicine. Genetic variations in loci associated with HbF induction and drug metabolism are prime targets for hydroxyurea (HU) pharmacogenomics. This study investigated genetic variations in BCL11A, ARG2, HBB, HBG1, WAC, HBG2, HAO2, MYB, SAR1A, KLF10, CYP2C9, CYP2E1 and NOS1 as potential HU pharmacogenomics targets. The panel was designed using the Illumina Design Studio (Illumina, San Diego, CA, USA) and achieved a total coverage of 96% of all genomic targets over a span of 51.6 kilobases (kb). We are reporting a successfully designed Illumina (MiSeq) HU pharmacogenomics custom panel encompassing 51.6 kilobases. The designed panel achieved greater than 1000x amplicon coverage which is which is sufficient for genomic analysis. Therefore, this study provides a valuable tool for research in HU pharmacogenomics, especially in Africa.Keywords
All Related Versions
- Version 1, 2023-08-25, Research Square
- Published version: BMC Medical Genomics, 17 (1), 190.
This publication has 16 references indexed in Scilit:
- Role of pharmacogenetics in public health and clinical health care: a SWOT analysisEuropean Journal of Human Genetics, 2016
- Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell AnemiaPLOS ONE, 2014
- Emerging science of hydroxyurea therapy for pediatric sickle cell diseasePediatric Research, 2013
- Three fingers on the switchCurrent Opinion in Hematology, 2013
- Fetal hemoglobin in sickle cell anemiaBlood, 2011
- Transcellular movement of hydroxyurea is mediated by specific solute carrier transportersExperimental Hematology, 2011
- A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary erythroid cellsGenome Research, 2010
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)Blood, 2010
- Hydroxyurea for the Treatment of Sickle Cell AnemiaNew England Journal of Medicine, 2008
- Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapyBlood, 2002